Evidence map›Paper›PMID 40891819›Full record

Trial reportMicrobiology spectrum2025

Ilke De Boeck, Irina Spacova, Eline Cauwenberghs, Tom Eilers, Thies Gehrmann, Karlien Van den Bossche, Katleen Martens, Sandra Condori-Catachura, Kato Michiels, Fien De Winter and 8 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ilke De Boeck *Laboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.ORCID 0000-0003-0764-8515
Irina Spacova *Laboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.ORCID 0000-0003-0562-7489
Eline CauwenberghsLaboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.
Tom EilersLaboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.
Thies GehrmannLaboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.
Karlien Van den BosscheFaculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
Katleen MartensDepartment of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.
Sandra Condori-CatachuraLaboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.
Kato MichielsLaboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.
Fien De WinterMolecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
Samir Kumar-SinghMolecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
Nicolas BruffaertsService Mycology & Aerobiology, Sciensano, Brussels, Belgium.
Ann PackeuService Mycology & Aerobiology, Sciensano, Brussels, Belgium.
Peter W HellingsDepartment of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.
Anneclaire VroegopFaculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
Klara Van GoolENT Kalmthout, Kalmthout, Belgium.
Olivier M VandervekenFaculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
Sarah LebeerLaboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-9400-6918

Funding

European Research Council 852600Fonds Wetenschappelijk Onderzoek 1277222NFonds Wetenschappelijk Onderzoek 12S4222NFonds Wetenschappelijk Onderzoek 12Z0622NiBOF POSSIBL
6 · The paper itself

Abstract

Current treatments fall short in managing allergic rhinitis (AR), emphasizing the need for additional strategies. Beneficial bacteria application shows promise in AR; however, most studies focus on oral probiotic administration without monitoring the applied strains in the upper respiratory tract (URT) and their local effects. In this randomized, double-blind, placebo-controlled trial, the probiotic

Indexed as

Lacticaseibacillus rhamnosusNoseProbioticsRhinitis, AllergicRhinitis, Allergic, SeasonalAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedPollenYoung Adultallergyhuman microbiomeLacticaseibacillusprobiotics

Identifiers

PMID40891819
PMCPMC12502598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.